Eyre et al (medrxiv.org/content/10.110…) is a tour-de-force. Bravo!
- traced 150k contacts from 100k cases (! - NHS👏🏽)
- Pfizer vax'd index cases had ~5x (Alpha) or 3x (Delta) lower odds of spreading (this is beyond protection by preventing the index case to begin with)
🧵 1/6
2/6
- this despite similar cycle thresholds (Ct) in vax'd vs unvax'd index Delta cases, as others have shown
- Pfizer vax'd contacts had 16x (Alpha) or 10x (Delta) lower odds of being infected
- Ct is not infectivity
- Ct is not infectivity
- Ct is not infectivity
- #VaccinesWork
3/6
- they also saw waning, c/w other studies (incl imo the best studies, the post-hoc crossover analyses of mRNA RCTs). Here, they found 1.2x increased odds of transmission "for each doubling of weeks since 14 days after 2nd vax in index cases" (?), & 1.4x increase in contacts.
4/6
- interestingly, though Pfizer worked better than AZ against Delta overall, it also seemed to wane quicker, at least for protecting contacts (p = 0.002). Similar results seen elsewhere w/ J&J (less waning). Seems like support for 6 mo boost of mRNA vax (hopefully just x1)?
5/6
- contacts of asymptomatic index cases were less likely to test +, but this was more true for Alpha (>3x lower odds) than Delta (<2x lower odds)
- vax lowered measured VL in Alpha but not Delta cases
- higher VL transmitted more than lower VL, but vax helped at any VL (Ct)
6/6
Summary of a super-rich paper: Delta sucks, vaccines work less well against it that Alpha and wane a bit, but they still work really, really well (10x lower odds of being infected, 3x lower odds of spreading if infected).

Score another one for UK NHS (Test & Trace)👏🏽

#VaxUp
Btw, sometimes when I describe papers as "super-rich", it's code for "complicated".

This preprint isn't that. It's clearly written, & w/in limits of my ability to assess, very well done. It's super-rich b/c they traced 100,000 cases to 150,000 contacts FFS!!! Well worth a read.
Important point raised by @CrazyTalk : the odds ratios I cited throughout this thread come from Table 1 and are basically maximal activity (estimated at 14d post-dose 2); they wane from there.

Yet another good point (h/t @MarvinH2_G2): since this is a UK study, it probably reflects longer dose interval b/w Pfizer doses. No controlled data I'm aware of on how this would matter, but I might expect more waning w/ the standard 3 wk interval.

My takeaways:
- vaccines protect you from getting infected (but aren't perfect)
- if infected, vaccines reduce risk of transmitting to others (but aren't perfect - less good at this)
- both wane
- they're the most important intervention, but not the only needed w/ Delta raging
Anyway, glad ppl seem to be enjoying this thread. I've learned a lot from the discussion already, but I have to get to work on 5 grants due this month (that's at least 2 too many!!!)

Please, read the preprint! Layers of nuance I had to simplify #onhere

medrxiv.org/content/10.110…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Roby Bhattacharyya

Roby Bhattacharyya Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @roby_bhatt

29 Dec 20
At the risk of shouting into the void, 🧵 on papers from 2020 that most changed how I think abt COVID, as an ID physician-scientist. 280-char summaries + URLs for each. Thx to all authors & apologies for any omissions; this list is unofficial, personal, idiosyncratic, & LONG. 1/
2/ Early summary of 72,314 (hospitalized) cases from Chinese CDC, broken down by mild vs severe vs critical, early hint at CFR (overestimated b/c mild cases undersampled), & sharply age-dependent mortality. Also, risk to HCWs. Fig 1 (epidemic curve) key.

jamanetwork.com/journals/jama/…
3/ Another inpt obs cohort study from China 🙏🏽. Fig 2 shows prognostic biomarkers (lymphs, D-dimer, IL-6 – not CRP, despite my false memory). Watched (helplessly) a lot of these rise in worsening patients. Still wonder why we ordered so many, so often.

thelancet.com/journals/lance…
Read 38 tweets
6 Aug 20
NEJM editorial argues that low sensitivity tests are problematic
nejm.org/doi/full/10.10…

If the alternative is a perfect test, sure. But tests are still too scarce. We need more & faster tests; can sacrifice Se w/ clear communication

@michaelmina_lab @DanLarremore @RWalensky 🧵
2/8
From the editorial: "A big concern has been test availability, but test accuracy may prove a larger long-term problem."

I disagree w this framing: the two features are in direct tension. If we hold out for "perfectly" sensitive tests, we resign ourselves to less testing.
3/8
Great modeling studies from folks I tagged shows frequency/TAT are MUCH more impt than sensitivity:
medrxiv.org/content/10.110…

jamanetwork.com/journals/jaman…

Even w/o repeat tests, even one 70% Se test catches far more than no test at all. (& those it misses probably shed less virus)
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(